💊 Rivaroxaban (Xarelto)

🏷️ Brand names & manufacturers

Xarelto🏭 Janssen Pharmaceuticals, Inc.DailyMed

Rivaroxaban🏭 Dr.Reddy's Laboratories, Inc.DailyMed

Rivaroxaban🏭 XLCare Pharmaceuticals, Inc.DailyMed

Rivaroxaban🏭 ScieGen pharmaceuticals,IncDailyMed

✅ What it is used for

• Reduce risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillation
• Treatment of deep vein thrombosis (DVT)
• Treatment of pulmonary embolism (PE)
• Reduce the risk of recurrence of DVT and/or PE
• Prophylaxis of DVT after hip or knee replacement surgery
• Prophylaxis of venous thromboembolism in acutely ill medical patients not at high risk of bleeding
• Reduce risk of major cardiovascular events in coronary artery disease (CAD)
• Reduce risk of major thrombotic vascular events in peripheral artery disease (PAD), including after recent lower extremity revascularization
• Treatment of VTE and reduction of recurrent VTE in pediatric patients from birth to less than 18 years
• Thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure

🧪 Active ingredient

Rivaroxaban: a selective factor Xa inhibitor that reduces thrombin generation and thereby limits blood clotting.

🌿 Benefits

• Reduces the risk of stroke and systemic embolism in nonvalvular atrial fibrillation
• Treats DVT and PE and reduces their recurrence
• Helps prevent clots after joint replacement surgery and in some hospitalized medical patients
• Reduces major cardiovascular and thrombotic events in patients with CAD or PAD

📝 How to use

• The dose and duration are set by your doctor or pharmacist based on your condition and kidney function; do not change it yourself
• For atrial fibrillation, the dose is usually taken with the evening meal
• For DVT/PE treatment, take with food at the same time each day
• For some uses it can be taken with or without food, as directed by your doctor
• Do not stop taking it on your own, as this increases the risk of clots

💊 Dosage forms

• Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg
• Granules for oral suspension: 1 mg/mL once reconstituted

🔄 Drug interactions

• Avoid combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole, ritonavir), which raise exposure and bleeding risk
• Avoid combined P-gp and strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort), which reduce effectiveness
• Other anticoagulants: avoid concurrent use
• Aspirin, clopidogrel, chronic NSAIDs, enoxaparin and warfarin may increase bleeding risk
• SSRIs and SNRIs may increase bleeding risk
• Combined P-gp and moderate CYP3A inhibitors (e.g., erythromycin) in patients with CrCl 15 to <80 mL/min: avoid unless the potential benefit justifies the risk

📍 Find the nearest pharmacy

Your location is used only in your browser to show nearby pharmacies — we don't store it.

👨‍⚕️ For healthcare professionals

Mechanism of action

Selective factor Xa inhibitor requiring no cofactor (e.g., antithrombin III); inhibits free FXa and prothrombinase activity, decreasing thrombin generation. No direct effect on platelet aggregation, but indirectly inhibits thrombin-induced platelet aggregation.

Labeled dosing

General adult dosing per label: nonvalvular AF 20 mg once daily with the evening meal (15 mg if CrCl ≤50 mL/min); DVT/PE treatment 15 mg twice daily for 21 days then 20 mg once daily with food; reduction of DVT/PE recurrence 10 mg once daily after at least 6 months of standard treatment; prophylaxis after hip surgery 10 mg daily for 35 days and after knee surgery for 12 days; prophylaxis in acutely ill medical patients 10 mg daily for 31–39 days; CAD/PAD 2.5 mg twice daily plus aspirin 75–100 mg daily. The actual dose is determined by the prescriber.

• Avoid use if CrCl <15 mL/min for DVT/PE treatment and prophylaxis indications
• Monitoring anticoagulant effect with anti-FXa activity or clotting tests is not recommended
• Terminal half-life is 5 to 9 hours in healthy subjects aged 20 to 45 years
• No specific agent to reverse anti-Xa activity is available; partial reversal of laboratory parameters may be achieved with plasma products
• Systemic exposure does not increase further at single doses >50 mg due to limited absorption

🎓 Key points for students

• Class: factor Xa inhibitor (EPC); mechanism is inhibition of free FXa and prothrombinase
• Substrate of CYP3A4/5, CYP2J2, and the P-gp and ABCG2 transporters
• Boxed warning: premature discontinuation increases thrombotic events + spinal/epidural hematoma
• Combined P-gp/strong CYP3A inhibitors raise exposure; inducers lower it
• Most common adverse reaction is bleeding; no specific reversal agent available